Alnylam Pharmaceuticals | ALNY - Net Income


Alnylam Pharmaceuticals reported $205.99M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 3.64M 269.93M Mar/2026
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Alnylam Pharmaceuticals USD 205.99M 19.57M Mar/2026
Amgen USD 1.82B 486M Mar/2026
Arrowhead Research USD -132.73M 163.54M Mar/2026
BioCryst Pharmaceuticals USD 245.84M 232.95M Dec/2025
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Incyte USD 303.33M 4.05M Mar/2026
Ionis Pharmaceuticals USD -93M 136M Mar/2026
Moderna USD -1.34B 517M Mar/2026
Neurocrine Biosciences USD 197.9M 44.2M Mar/2026
Novartis USD 3.16B 747M Mar/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sanofi EUR 1.61B 2.42B Mar/2026
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Takeda JPY -24.32B 127.96B Mar/2026
Tectonic Therapeutic USD -25.24M 6.02M Mar/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vertex Pharmaceuticals USD 1.03B 159.7M Mar/2026
Xencor USD -128.92M 122.26M Mar/2026